Comparison of Serum Hemagglutinin and Neuraminidase Inhibition Antibodies After 2010–2011 Trivalent Inactivated Influenza Vaccination in Healthcare Personnel

Laguio-Vila, Maryrose; Thompson, Mark G.; Reynolds, Sue; Spencer, Sarah; Gaglani, Manjusha; Naleway, Allison L.; Ball, Sarah; Bozeman, Sam; Baker, Steven F.; Martínez-Sobrido, Luis; Levine, Min Z.; Katz, Jackie; Fry, Alicia M.; Treanor, John J.

doi:10.1093/ofid/ofu115

Cited by 28 publications

(20 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sera from ferrets infected with A/Cal/07/09 (BEI Resources; NR-15429) and patient sera collected at days 0 and 28 were tested in duplicate against sciIAV-NA-wt and sciIAV-NA-001 for NAI Ab titers using a modified enzyme-linked lectin-based assay (ELLA), as previously described [ 19 , 35 , 36 ]. Bound lectin was detected with 3,3',5,5'-tetramethylbenzidine (TMB) (Thermo Scientific #34028), and optical density was measured at 450 nm.…”

Section: Methodsmentioning

confidence: 99%

Antigenicity of the 2015–2016 seasonal H1N1 human influenza virus HA and NA proteins

et al. 2017

View full text Add to dashboard Cite

Antigenic drift of the hemagglutinin (HA) and neuraminidase (NA) influenza virus proteins contributes to reduced vaccine efficacy. To analyze antigenic drift in human seasonal H1N1 viruses derived from the 2009 pandemic H1N1 virus (pH1N1-like viruses) accounts for the limited effectiveness (around 40%) of vaccination against pH1N1-like viruses during the 2015–2016 season, nasal washes/swabs collected from adult subjects in the Rochester, NY area, were used to sequence and isolate the circulating viruses. The HA and NA proteins from viruses circulating during the 2015–2016 season encoded eighteen and fourteen amino acid differences, respectively, when compared to A/California/04/2009, a strain circulating at the origin of the 2009 pandemic. The circulating strains belonged to subclade 6B.1, defined by HA amino acid substitutions S101N, S179N, and I233T. Hemagglutination-inhibiting (HAI) and HA-specific neutralizing serum antibody (Ab) titers from around 50% of pH1N1-like virus-infected subjects and immune ferrets were 2–4 fold lower for the 2015–2016 circulating strains compared to the vaccine strain. In addition, using a luminex-based mPlex HA assay, the binding of human sera from subjects infected with pH1N1-like viruses to the HA proteins from circulating and vaccine strains was not identical, strongly suggesting antigenic differences in the HA protein. Additionally, NA inhibition (NAI) Ab titers in human sera from pH1N1-like virus-infected subjects increased after the infection and there were measurable antigenic differences between the NA protein of circulating strains and the vaccine strain using both ferret and human antisera. Despite having been vaccinated, infected subjects exhibited low HAI Ab titers against the vaccine and circulating strains. This suggests that poor responses to the H1N1 component of the vaccine as well as antigenic differences in the HA and NA proteins of currently circulating pH1N1-like viruses could be contributing to risk of infection even after vaccination.

show abstract

Section: Methodsmentioning

confidence: 99%

Antigenicity of the 2015–2016 seasonal H1N1 human influenza virus HA and NA proteins

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Details of our study methodology have been previously published, including: study recruitment (from September to November 2010) and participant characteristics [7,8]; collection of blood at enrollment, ∼28 days post-vaccination (October to December 17, 2010), and ∼7 months after enrollment (May and June 2011) [9]; the documentation of vaccination status from integrated medical and employee records [7,10,11]; active surveillance for febrile acute respiratory illness (FARI; fever, feverishness, or chills and cough) [12,13] from December 18 2010 to April 30 2011; collection of three separate specimens using nasal, oropharyngeal, and nasopharyngeal swabs and testing each using US CDC's RT-PCR procedures [14]. Serum was tested by HI using standard procedures against the IIV3 components A/California/7/2009 (H1N1) (i.e., A[H1N1]pdm09) and A/Perth/16/2009-like H3N2 virus [9,15]; all of the influenza A viruses from our study were characterized as vaccine-like [9,15] similar to national trends that season [16]. We define seroconversion as a ≥4-fold increase in geometric mean titers (GMT) to either A viruses from T1 (baseline) to T3 (post-season) for unvaccinated HCP and from T2 (∼28 days post-vaccination) to T3 for vaccinees.…”

Section: Methodsmentioning

confidence: 99%

Reduced serologic sensitivity to influenza A virus illness among inactivated influenza vaccinees

Thompson

Gaglani

Naleway

et al. 2016

Vaccine

Self Cite

View full text Add to dashboard Cite

“…Neuraminidase-specific antibodies have been shown to play a role in protection against influenza infection [ 36 , 37 ]. However, many questions remain about the role of neuraminidase in vaccine effectiveness [ 38 ].…”

Section: Methodsmentioning

confidence: 99%

Study of Healthcare Personnel with Influenza and other Respiratory Viruses in Israel (SHIRI): study protocol

et al. 2018

Self Cite

View full text Add to dashboard Cite

BackgroundThe Study of Healthcare Personnel with Influenza and other Respiratory Viruses in Israel (SHIRI) prospectively follows a cohort of healthcare personnel (HCP) in two hospitals in Israel. SHIRI will describe the frequency of influenza virus infections among HCP, identify predictors of vaccine acceptance, examine how repeated influenza vaccination may modify immunogenicity, and evaluate influenza vaccine effectiveness in preventing influenza illness and missed work.MethodsCohort enrollment began in October, 2016; a second year of the study and a second wave of cohort enrollment began in June 2017. The study will run for at least 3 years and will follow approximately 2000 HCP (who are both employees and members of Clalit Health Services [CHS]) with routine direct patient contact. Eligible HCP are recruited using a stratified sampling strategy. After informed consent, participants complete a brief enrollment survey with questions about occupational responsibilities and knowledge, attitudes, and practices about influenza vaccines. Blood samples are collected at enrollment and at the end of influenza season; HCP who choose to be vaccinated contribute additional blood one month after vaccination. During the influenza season, participants receive twice-weekly short message service (SMS) messages asking them if they have acute respiratory illness or febrile illness (ARFI) symptoms. Ill participants receive follow-up SMS messages to confirm illness symptoms and duration and are asked to self-collect a nasal swab. Information on socio-economic characteristics, current and past medical conditions, medical care utilization and vaccination history is extracted from the CHS database. Information about missed work due to illness is obtained by self-report and from employee records. Respiratory specimens from self-collected nasal swabs are tested for influenza A and B viruses, respiratory syncytial virus, human metapneumovirus, and coronaviruses using validated multiplex quantitative real-time reverse transcription polymerase chain reaction assays. The hemagglutination inhibition assay will be used to detect the presence of neutralizing influenza antibodies in serum.DiscussionSHIRI will expand our knowledge of the burden of respiratory viral infections among HCP and the effectiveness of current and repeated annual influenza vaccination in preventing influenza illness, medical utilization, and missed workdays among HCP who are in direct contact with patients.Trial registrationNCT03331991. Registered on November 6, 2017.Electronic supplementary materialThe online version of this article (10.1186/s12879-018-3444-7) contains supplementary material, which is available to authorized users.

show abstract

Comparison of Serum Hemagglutinin and Neuraminidase Inhibition Antibodies After 2010–2011 Trivalent Inactivated Influenza Vaccination in Healthcare Personnel

Cited by 28 publications

References 32 publications

Antigenicity of the 2015–2016 seasonal H1N1 human influenza virus HA and NA proteins

Antigenicity of the 2015–2016 seasonal H1N1 human influenza virus HA and NA proteins

Reduced serologic sensitivity to influenza A virus illness among inactivated influenza vaccinees

Study of Healthcare Personnel with Influenza and other Respiratory Viruses in Israel (SHIRI): study protocol

Contact Info

Product

Resources

About